Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. raised its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 43.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,263,353 shares of the company’s stock after acquiring an additional 382,608 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 1.84% of Amylyx Pharmaceuticals worth $4,775,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Walleye Capital LLC lifted its holdings in Amylyx Pharmaceuticals by 986.5% in the third quarter. Walleye Capital LLC now owns 670,594 shares of the company’s stock valued at $2,173,000 after acquiring an additional 608,874 shares during the period. Alpha Wave Global LP acquired a new position in Amylyx Pharmaceuticals in the third quarter valued at approximately $2,169,000. Geode Capital Management LLC lifted its holdings in Amylyx Pharmaceuticals by 17.5% in the third quarter. Geode Capital Management LLC now owns 551,039 shares of the company’s stock valued at $1,786,000 after acquiring an additional 82,173 shares during the period. FMR LLC lifted its holdings in Amylyx Pharmaceuticals by 292.0% in the third quarter. FMR LLC now owns 221,001 shares of the company’s stock valued at $716,000 after acquiring an additional 164,622 shares during the period. Finally, JPMorgan Chase & Co. increased its position in shares of Amylyx Pharmaceuticals by 144.4% in the third quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock valued at $455,000 after buying an additional 83,048 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AMLX. Baird R W upgraded Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 18th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Amylyx Pharmaceuticals in a research report on Wednesday, March 5th. Finally, Robert W. Baird upgraded Amylyx Pharmaceuticals from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $3.00 to $11.00 in a research report on Monday, November 18th. Three investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $7.33.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX opened at $3.63 on Monday. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $7.27. The stock has a market capitalization of $321.63 million, a price-to-earnings ratio of -0.95 and a beta of -0.51. The stock has a 50 day moving average price of $3.51 and a 200 day moving average price of $3.94.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Tuesday, March 4th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The company had revenue of ($0.67) million during the quarter. On average, analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Insider Buying and Selling

In other Amylyx Pharmaceuticals news, CEO Justin B. Klee sold 7,471 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $4.04, for a total transaction of $30,182.84. Following the transaction, the chief executive officer now owns 3,176,788 shares of the company’s stock, valued at approximately $12,834,223.52. The trade was a 0.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Joshua B. Cohen sold 11,851 shares of the business’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $3.47, for a total value of $41,122.97. Following the transaction, the chief executive officer now directly owns 3,201,247 shares in the company, valued at $11,108,327.09. This trade represents a 0.37 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,169 shares of company stock worth $97,274. 11.70% of the stock is owned by corporate insiders.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.